Skip to content
Life Sciences Series B Founded 2017

NeoPhore

Developer of small molecule therapies to treat cancer. The therapies target genetic mechanisms to create neoantigen which stimulates the immune system. The company engages in the inactivation of the DNA mismatch repair (MMR) gene which promotes neoantigen creation and provides immunity against numerous cancers. The company was founded in 2017 and headquartered in Cambridge, United Kingdom. It has raised $44.6M in…

📍 Cambridge, United Kingdom · Genomics,

Funding snapshot

Last roundSeries B
Amount$12M
Date1 February 2024
Total raised$45M
Team size10

About

Developer of small molecule therapies to treat cancer. The therapies target genetic mechanisms to create neoantigen which stimulates the immune system. The company engages in the inactivation of the DNA mismatch repair (MMR) gene which promotes neoantigen creation and provides immunity against numerous cancers. The company was founded in 2017 and headquartered in Cambridge, United Kingdom. It has raised $44.6M in series b funding, with backing from Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2Invest, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Oncology space. Its offerings span Oncology - Drugs - Pan Cancer and Genomics - Genomics Research - Biomarker Discovery.

Business model

Oncology > Drugs > Pan Cancer,

Genomics > Genomics Research > Biomarker Discovery

Team background

College Wise > Harvard University

Institutional investors

Claris Ventures Astellas Venture Management 3B Future Health Fund 2Invest Cancer Research Horizons Sixth Element Capital Parkwalk Bristol-Myers Squibb 2invest AG Neva SGR LIFTT o2h ventures

Latest coverage

No articles yet.

Raising like NeoPhore?

Analyze your pitch deck before your next raise.

Analyze My Deck →